Clicky

Exscientia Limited(EXAI)

Description: Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our pipeline demonstrates our ability to rapidly translate scientific concepts into precision-designed therapeutic candidates, with more than 25 projects advancing, including the first three AI-designed drug candidates to enter Phase 1 clinical trials.


Keywords: Life Sciences Artificial Intelligence Health Sciences Clinical Trial Clinical Pharmacology Precision Medicine Systems Biology Evidence Based Medicine

Home Page: www.exscientia.ai

EXAI Technical Analysis

The SchrOedinger Building
Oxford, OX4 4GE
United Kingdom
Phone: 44 18 6581 8941


Officers

Name Title
Prof. Andrew L. Hopkins DPHIL, FRSE FRSC Founder, CEO & Exec. Director
Mr. Ben Ashwell-Fryer VP of Fin.
Mr. Ben R. Taylor CFO, Chief Strategy Officer & Exec. Director
Ms. Heather Togwell Operations Mang.
Ms. Margo Mosley VP of Facilities & Operations
Dr. Garry Pairaudeau Ph.D. Chief Technology Officer
Dr. David Hallett Ph.D. Chief Scientific Officer
Ms. Eileen Jennings-Brown Chief Information Officer
Ms. Sara Sherman VP of Investor Relations
Mr. Dan Ireland VP of Legal

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1.0044
Price-to-Sales TTM: 23.3243
IPO Date: 2021-10-01
Fiscal Year End: December
Full Time Employees: 285
Back to stocks